Pharmacotherapy and adjunctive treatment for idiopathic pulmonary fibrosis (IPF)

Saito, Shigeki; Alkhatib, Ala; Kolls, Jay; Kondoh, Yasuhiro; Lasky, Joseph A.

doi:10.21037/jtd.2019.04.62

Cited by 97 publications

(74 citation statements)

References 100 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…LPA is highly abundant in multiple respiratory diseases and blocking ATX/LPA signaling could alleviate those diseases [6,19]. Even though the pathological roles of LPA in cows have not been fully investigated in vivo until now, many in vitro studies in other animal models, including humans, strongly suggest that LPA importantly works in multiple respiratory diseases [6,12,19]. Furthermore, there are interesting in vivo studies in cattle for development of reproductive diseases and development of embryos [20,21].…”

Section: Discussionmentioning

confidence: 99%

“…LPA is synthesized by autotaxin (lysophospholipase D), which removes the choline group from lysophosphatidylcholine or by synthesis of phosphatidic acid [10,11]. Importantly, LPA plays a key role in pulmonary diseases [6], and serves as a therapeutic target for treating refractory idiopathic pulmonary fibrosis [12], which is caused by dust, air pollution, and microbes as well as endogenous factors such as LPA. In addition, pathogenic angiogenesis is critical for inflammatory diseases including respiratory diseases, and LPA is a potent stimulator of this process in multiple diseases [13,14].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

KA-1002, a Novel Lysophosphatidic Acid Signaling Antagonist, Alleviates Bovine Tracheal Cell Disruption and Inflammation

Shin

Kim

et al. 2020

Animals

View full text Add to dashboard Cite

The industrial livestock environment can cause stress and weakened immunity in cattle, leading to microbial infections which reduce productivity. As such, there is a need for an effective therapeutic agent that can alleviate uncontrolled destructive respiratory inflammation. We found that lysophosphatidic acid (LPA), a potent endogenous stress-induced inflammatory agent, causes respiratory tissue damage and triggers inflammation in bovine bronchial cells. LPA also inflames pulmonary bovine blood vessel cells to produce inflammatory cytokines. These findings strongly suggest that LPA is a highly important endogenous material exacerbating bovine respiratory diseases. We further identified a novel LPA-signaling antagonist, KA-1002, and showed that it alleviated LPA-mediated bovine tracheal cell disruption and inflammation. Therefore, KA-1002 could potentially serve as a novel therapeutic agent to maintain physiologically healthy and balanced conditions in bovine respiratory tracts.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

KA-1002, a Novel Lysophosphatidic Acid Signaling Antagonist, Alleviates Bovine Tracheal Cell Disruption and Inflammation

Shin

Kim

et al. 2020

Animals

View full text Add to dashboard Cite

show abstract

“…A recent large database study by Demsey et al reported a decreased mortality risk in IPF patients in the first 2 years of anti-fibrotic treatment [31]. However, it is challenging to pinpoint a single factor that lead to this encouraging result based on our study especially when antifibrotic therapies were only approved since 2014 [32].…”

Section: Discussionmentioning

confidence: 73%

Trends and seasonal variation of hospitalization and mortality of interstitial lung disease in the United States from 2006 to 2016

Shmelev

Charbek

2020

Respir Res

View full text Add to dashboard Cite

Background: In the recent years, the overall trends in hospital admission and mortality of interstitial lung disease (ILD) are unknown. In addition, there was some evidence that interstitial lung disease death rate highest in the winter but this finding was only available in one study. This study will investigate the trend and seasonal variations in hospital admission and mortality rates of ILD from 2006 to 2016. Method: From the Nationwide Inpatient Sample database, we collected all cases with the International Classification of Diseases (ICD)-9 or ICD-10 codes of ILD excluding identifiable external causes (drug, organic or inorganic dusts) from 2006 to 2016. Hospitalization rates of each year were calculated based on U.S Census population data. Monthly hospitalization and in-hospital mortality rates were analyzed by seasonal and trend decomposition. Subgroups of idiopathic interstitial fibrosis (IPF), acute respiratory failure (ARF), pneumonia were analyzed. Results: From 2006 to 2016, all-cause hospital admission rate of patients with interstitial lung disease (ILD) and IPFonly subgroup declined but their overall mortality remained unchanged (except IPF subgroup and acute respiratory failure subgroup). Acute respiratory failure related admission account for 23% of all causes and pneumonia 17.6%. Mortality of ILD in general and subgroup of ILD with ARF was highest in winter, up to 8.13% ± 0.60 and 26.3% ± 10.2% respectively. The seasonal variations of hospital admission and mortality of ILD in general was not changed when infectious pneumonia cases were ruled out. All cause admission rates were highest in months from January to April. Subgroup analysis also showed seasonal variations with highest hospitalization rates for all subgroups (IPF, ARF, pneumonia) in the months from December to April (winter to early Spring). Conclusion: From 2006 to 2016, admission rates of ILD of all causes and IPF subgroup declined but in-hospital mortality of ILD of all causes remained unchanged. Mortality of IPF subgroup and acute respiratory failure subgroup trended down. All-cause hospital admissions and mortality of ILD have a strong seasonal variation. Hospitalization rates for all subgroups (IPF, ARF, pneumonia) were highest in the months from December to April.

show abstract

“…[ 16 – 18 ] So far, there is no satisfactory treatment for pulmonary fibrosis. [ 19 , 20 ] Commonly used drugs include glucocorticoids, immunosuppressants/cytotoxic drugs, and antifibrotic agents. [ 21 ] Danhong injection is principally composed of salvia miltiorrhiza and safflower extracts, and it has been demonstrated to improve the degree of pulmonary fibrosis.…”

Section: Discussionmentioning

confidence: 99%

Danhong injection in the treatment of idiopathic pulmonary fibrosis

Lan¹,

Wu²,

Jin

et al. 2020

Medicine

View full text Add to dashboard Cite

Background: Many studies have reported that the effects of danhong injection on idiopathic pulmonary fibrosis. However, its effects are still not well understood. The aim of this study is to assess the effects of danhong injection in the management of idiopathic pulmonary fibrosis. Methods: Electronic databases such as PubMed, MEDLINE, EMbase, Web of Science, Cochrane Library, China National Knowledge Infrastructure, WanFang, the Chongqing VIP Chinese Science and Technology Periodical Database, and China biomedical literature database will be searched without limitations of language and geographical location. Two researchers will independently conduct research selection, data extraction, and research quality assessment. The RevMan 5.3 software and Stata 14.0 software are used for statistical analysis. Results: This study will provide high-quality comprehensive evidence for the effectiveness and safety of danhong injection in the treatment of idiopathic pulmonary fibrosis. Conclusions: The results obtained from this study will define the basis for the effectiveness and safety of danhong injection in the treatment of idiopathic pulmonary fibrosis.

show abstract

Pharmacotherapy and adjunctive treatment for idiopathic pulmonary fibrosis (IPF)

Cited by 97 publications

References 100 publications

KA-1002, a Novel Lysophosphatidic Acid Signaling Antagonist, Alleviates Bovine Tracheal Cell Disruption and Inflammation

KA-1002, a Novel Lysophosphatidic Acid Signaling Antagonist, Alleviates Bovine Tracheal Cell Disruption and Inflammation

Trends and seasonal variation of hospitalization and mortality of interstitial lung disease in the United States from 2006 to 2016

Danhong injection in the treatment of idiopathic pulmonary fibrosis

Contact Info

Product

Resources

About